Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer

Bone Marrow Transplantation

Volumn 25, Issue 10, 2000, Pages 1047-1052

  Klein, J L ^a,b   Maroto Rey, P ^a   Dansey, R D ^a   Karanes, C ^a   Du, W ^a   Abella, E ^a   Cassells, L ^a   Hamm, C ^a   Peters, W P ^a   Baynes, R D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of Hematology and Oncology   (United States)

Author keywords

Autologous; Breast cancer; Cardiotoxicity; Doxorubicin; Transplantation

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DIGOXIN; DIURETIC AGENT; DOXORUBICIN; PACLITAXEL; RADIOISOTOPE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG TOLERABILITY; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; NEUTROPENIA; PRIORITY JOURNAL; VASODILATATION;

EID: 12944305875     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702394     Document Type: Article

References (20)

1. Peters WP, Jones RB, Vredenburgh J et al. A large prospective, randomized trial of high-dose alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc Am Soc Clin Oncol 1996; 15: 121 (Abstr. 149).
2. Buzdar AU, Holmes FA, Hortobagyi GN. Paclitaxel in the treatment of metastatic breast cancer: MD Anderson Cancer Center experience. Semin Oncol 1995; 22: 101-104.
3. Gianni L, Munzone E, Capra G et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995; 87: 1169-1175.
4. Sledge GW, Robert N, Sparano JA et al. Paclitaxel (Taxol)/doxorubicin combination in advanced breast cancer: The Eastern Cooperative Oncology Group Experience. Semin Oncol 1994; 21 (Suppl. 8): 15-18.
5. Amadori D, Frassineti GL, Zolli W et al. A phase I/II study of paclitaxel and doxorubicin in the treatment of advanced breast cancer. Semin Oncol 1996; 23: 16-21.
6. Sledge GW. Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: The Eastern Cooperative Oncology Group experience. Semin Oncol 1995; 22 (Suppl. 12): 123-125.
7. O'Shaughnessy JA, Fisherman JS, Cowan KH. Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer. Semin Oncol 1994; 21 (Suppl. 8): 19-23.
8. Gianni L, Munzone E, Capri G et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688-2699.
9. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 707-710.
10. Shan K, Lincoff M, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 47-58.
11. Hudis C, Riccio Lm Seidman A et al. Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel. Cancer Invest 1998; 16: 67-71.
12. Holmes FA, Valero V, Walters RS et al. The MD Anderson Cancer Center experience with taxol in metastatic breast cancer. Monogr Natl Cancer Inst 1993; 15: 161-169.
13. Gianni L, Vigano L, Locatelli A et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 1997; 15: 1906-1915.
14. Goldberg MA, Antin JH, Guinan EC et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986; 68: 1114-1118.
15. Steinerz, LJ, Steinherz PG, Mangiacasale D et al. Cardiac changes with cyclophosphamide. Med Pediatr Onco 1981; 9: 417-422.
16. Kupari M, Volin L, Suokas A et al. Cardiac involvement in bone marrow transplant: electrocardiograpghic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant 1990; 5: 91-98.
17. Peters WP, Stuart A, Klotman M et al. High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. Cancer Chemother Pharmacol 1989; 23: 377-383.
18. Ayash L, Wright JE, Tretyako O et al. Cyclophosphamide pharmocokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992; 10: 995-1000.
19. Bearman SI, Petersen FB, Schor RA et al. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. Bone Marrow Transplant 1990; 5: 173-177.
20. Hertenstein B, Stefanic M, Schmeiser T et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. J Clin Oncol 1994; 12: 998-1004.